Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 56 of 56 entries
Sorted by: Best Match Show Resources per page
Improving Endothelial Explant Tissue Culture by Novel Thermoresponsive Cell Culture System.

Current eye research

Miron A, Spinozzi D, Lie J, Melles GR, Oellerich S, Ni Dhubhghaill S.
PMID: 32727221
Curr Eye Res. 2021 Mar;46(3):290-293. doi: 10.1080/02713683.2020.1798468. Epub 2020 Jul 29.

AIM: Studying cell migration of corneal endothelial cells MATERIALS AND METHODS: As a test tissue, fifteen Quarter-Descemet membrane endothelial keratoplasty (Q-DMEK) grafts were used that were embedded in a three-dimensional culture system using a temperature-reversible hydrogel and cultured over...

Cite
Miron A, Spinozzi D, Lie J, et al. Improving Endothelial Explant Tissue Culture by Novel Thermoresponsive Cell Culture System. Curr Eye Res. 2020;46(3):290-293doi: 10.1080/02713683.2020.1798468.
Miron, A., Spinozzi, D., Lie, J., Melles, G. R., Oellerich, S., & Ni Dhubhghaill, S. (2021). Improving Endothelial Explant Tissue Culture by Novel Thermoresponsive Cell Culture System. Current eye research, 46(3), 290-293. https://doi.org/10.1080/02713683.2020.1798468
Miron, Alina, et al. "Improving Endothelial Explant Tissue Culture by Novel Thermoresponsive Cell Culture System." Current eye research vol. 46,3 (2021): 290-293. doi: https://doi.org/10.1080/02713683.2020.1798468
Miron A, Spinozzi D, Lie J, Melles GR, Oellerich S, Ni Dhubhghaill S. Improving Endothelial Explant Tissue Culture by Novel Thermoresponsive Cell Culture System. Curr Eye Res. 2021 Mar;46(3):290-293. doi: 10.1080/02713683.2020.1798468. Epub 2020 Jul 29. PMID: 32727221.
Copy Download .nbib Format: NLM
Reply.

Cornea

Luceri S, Parker J, Dapena I, Baydoun L, Oellerich S, van Dijk K, Melles GR.
PMID: 28141743
Cornea. 2017 Mar;36(3):e8-e9. doi: 10.1097/ICO.0000000000001137.

No abstract available.

Cite
Luceri S, Parker J, Dapena I, et al. Reply. Cornea. 2017;36(3):e8-e9doi: 10.1097/ICO.0000000000001137.
Luceri, S., Parker, J., Dapena, I., Baydoun, L., Oellerich, S., van Dijk, K., & Melles, G. R. (2017). Reply. Cornea, 36(3), e8-e9. https://doi.org/10.1097/ICO.0000000000001137
Luceri, Salvatore, et al. "Reply." Cornea vol. 36,3 (2017): e8-e9. doi: https://doi.org/10.1097/ICO.0000000000001137
Luceri S, Parker J, Dapena I, Baydoun L, Oellerich S, van Dijk K, Melles GR. Reply. Cornea. 2017 Mar;36(3):e8-e9. doi: 10.1097/ICO.0000000000001137. PMID: 28141743.
Copy Download .nbib Format: NLM
Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Nature medicine

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J.
PMID: 28586337
Nat Med. 2017 Jun 06;23(6):788. doi: 10.1038/nm0617-788a.

No abstract available.

Cite
Schneider C, Oellerich T, Baldauf HM, et al. Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23(6):788doi: 10.1038/nm0617-788a.
Schneider, C., Oellerich, T., Baldauf, H. M., Schwarz, S. M., Thomas, D., Flick, R., Bohnenberger, H., Kaderali, L., Stegmann, L., Cremer, A., Martin, M., Lohmeyer, J., Michaelis, M., Hornung, V., Schliemann, C., Berdel, W. E., Hartmann, W., Wardelmann, E., Comoglio, F., Hansmann, M. L., Yakunin, A. F., Geisslinger, G., Ströbel, P., Ferreirós, N., Serve, H., Keppler, O. T., & Cinatl, J. (2017). Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nature medicine, 23(6), 788. https://doi.org/10.1038/nm0617-788a
Schneider, Constanze, et al. "Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia." Nature medicine vol. 23,6 (2017): 788. doi: https://doi.org/10.1038/nm0617-788a
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J. Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017 Jun 06;23(6):788. doi: 10.1038/nm0617-788a. PMID: 28586337.
Copy Download .nbib Format: NLM
Bowman layer transplantation in the treatment of keratoconus.

Eye and vision (London, England)

Dragnea DC, Birbal RS, Ham L, Dapena I, Oellerich S, van Dijk K, Melles GRJ.
PMID: 30238016
Eye Vis (Lond). 2018 Sep 12;5:24. doi: 10.1186/s40662-018-0117-y. eCollection 2018.

Several treatment options corresponding to the grade of keratoconus have been established. These are ultra-violet corneal crosslinking and intracorneal ring segments for mild to moderate keratoconus, and penetrating keratoplasty or deep anterior lamellar keratoplasty for the more advanced cases...

Cite
Dragnea DC, Birbal RS, Ham L, et al. Bowman layer transplantation in the treatment of keratoconus. Eye Vis (Lond). 2018;5:24doi: 10.1186/s40662-018-0117-y.
Dragnea, D. C., Birbal, R. S., Ham, L., Dapena, I., Oellerich, S., van Dijk, K., & Melles, G. R. J. (2018). Bowman layer transplantation in the treatment of keratoconus. Eye and vision (London, England), 524. https://doi.org/10.1186/s40662-018-0117-y
Dragnea, Diana C, et al. "Bowman layer transplantation in the treatment of keratoconus." Eye and vision (London, England) vol. 5 (2018): 24. doi: https://doi.org/10.1186/s40662-018-0117-y
Dragnea DC, Birbal RS, Ham L, Dapena I, Oellerich S, van Dijk K, Melles GRJ. Bowman layer transplantation in the treatment of keratoconus. Eye Vis (Lond). 2018 Sep 12;5:24. doi: 10.1186/s40662-018-0117-y. eCollection 2018. PMID: 30238016; PMCID: PMC6139901.
Copy Download .nbib Format: NLM
Corrigendum: A simple and versatile design concept for fluorophore derivatives with intramolecular photostabilization.

Nature communications

van der Velde JHM, Oelerich J, Huang J, Smit JH, Jazi AA, Galiani S, Kolmakov K, Gouridis G, Eggeling C, Herrmann A, Roelfes G, Cordes T.
PMID: 28776565
Nat Commun. 2017 Aug 04;8:16144. doi: 10.1038/ncomms16144.

This corrects the article DOI: 10.1038/ncomms10144.

Cite
van der Velde JHM, Oelerich J, Huang J, et al. Corrigendum: A simple and versatile design concept for fluorophore derivatives with intramolecular photostabilization. Nat Commun. 2017;8:16144doi: 10.1038/ncomms16144.
van der Velde, J. H. M., Oelerich, J., Huang, J., Smit, J. H., Jazi, A. A., Galiani, S., Kolmakov, K., Gouridis, G., Eggeling, C., Herrmann, A., Roelfes, G., & Cordes, T. (2017). Corrigendum: A simple and versatile design concept for fluorophore derivatives with intramolecular photostabilization. Nature communications, 816144. https://doi.org/10.1038/ncomms16144
van der Velde, Jasper H M, et al. "Corrigendum: A simple and versatile design concept for fluorophore derivatives with intramolecular photostabilization." Nature communications vol. 8 (2017): 16144. doi: https://doi.org/10.1038/ncomms16144
van der Velde JHM, Oelerich J, Huang J, Smit JH, Jazi AA, Galiani S, Kolmakov K, Gouridis G, Eggeling C, Herrmann A, Roelfes G, Cordes T. Corrigendum: A simple and versatile design concept for fluorophore derivatives with intramolecular photostabilization. Nat Commun. 2017 Aug 04;8:16144. doi: 10.1038/ncomms16144. PMID: 28776565; PMCID: PMC5547757.
Copy Download .nbib Format: NLM
PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.

Oncogenesis

Schneider L, Herkt S, Wang L, Feld C, Wesely J, Kuvardina ON, Meyer A, Oellerich T, Häupl B, Seifried E, Bonig H, Lausen J.
PMID: 34001852
Oncogenesis. 2021 May 17;10(5):42. doi: 10.1038/s41389-021-00332-z.

The establishment of cell type specific gene expression by transcription factors and their epigenetic cofactors is central for cell fate decisions. Protein arginine methyltransferase 6 (PRMT6) is an epigenetic regulator of gene expression mainly through methylating arginines at histone...

Cite
Schneider L, Herkt S, Wang L, et al. PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. Oncogenesis. 2021;10(5):42doi: 10.1038/s41389-021-00332-z.
Schneider, L., Herkt, S., Wang, L., Feld, C., Wesely, J., Kuvardina, O. N., Meyer, A., Oellerich, T., Häupl, B., Seifried, E., Bonig, H., & Lausen, J. (2021). PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. Oncogenesis, 10(5), 42. https://doi.org/10.1038/s41389-021-00332-z
Schneider, Lucas, et al. "PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1." Oncogenesis vol. 10,5 (2021): 42. doi: https://doi.org/10.1038/s41389-021-00332-z
Schneider L, Herkt S, Wang L, Feld C, Wesely J, Kuvardina ON, Meyer A, Oellerich T, Häupl B, Seifried E, Bonig H, Lausen J. PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. Oncogenesis. 2021 May 17;10(5):42. doi: 10.1038/s41389-021-00332-z. PMID: 34001852; PMCID: PMC8129428.
Copy Download .nbib Format: NLM
Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry.

The journal of pathology. Clinical research

Richter A, Fichtner A, Joost J, Brockmeyer P, Kauffmann P, Schliephake H, Hammerstein-Equord A, Kueffer S, Urlaub H, Oellerich T, Ströbel P, Bohnenberger H, Bremmer F.
PMID: 34647699
J Pathol Clin Res. 2022 Jan;8(1):33-47. doi: 10.1002/cjp2.244. Epub 2021 Oct 14.

The differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important...

Cite
Richter A, Fichtner A, Joost J, et al. Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. J Pathol Clin Res. 2021;8(1):33-47doi: 10.1002/cjp2.244.
Richter, A., Fichtner, A., Joost, J., Brockmeyer, P., Kauffmann, P., Schliephake, H., Hammerstein-Equord, A., Kueffer, S., Urlaub, H., Oellerich, T., Ströbel, P., Bohnenberger, H., & Bremmer, F. (2022). Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. The journal of pathology. Clinical research, 8(1), 33-47. https://doi.org/10.1002/cjp2.244
Richter, Annika, et al. "Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry." The journal of pathology. Clinical research vol. 8,1 (2022): 33-47. doi: https://doi.org/10.1002/cjp2.244
Richter A, Fichtner A, Joost J, Brockmeyer P, Kauffmann P, Schliephake H, Hammerstein-Equord A, Kueffer S, Urlaub H, Oellerich T, Ströbel P, Bohnenberger H, Bremmer F. Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. J Pathol Clin Res. 2022 Jan;8(1):33-47. doi: 10.1002/cjp2.244. Epub 2021 Oct 14. PMID: 34647699.
Copy Download .nbib Format: NLM
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.

Blood cancer discovery

Shaffer AL, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM.
PMID: 34778802
Blood Cancer Discov. 2021 Sep 14;2(6):630-647. doi: 10.1158/2643-3230.BCD-21-0063. eCollection 2021 Nov.

The use of Bruton tyrosine kinase (BTK) inhibitors to block B-cell receptor (BCR)-dependent NF-κB activation in lymphoid malignancies has been a major clinical advance, yet acquired therapeutic resistance is a recurring problem. We modeled the development of resistance to...

Cite
Shaffer AL, Phelan JD, Wang JQ, et al. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood Cancer Discov. 2021;2(6):630-647doi: 10.1158/2643-3230.BCD-21-0063.
Shaffer, A. L., Phelan, J. D., Wang, J. Q., Huang, D., Wright, G. W., Kasbekar, M., Choi, J., Young, R. M., Webster, D. E., Yang, Y., Zhao, H., Yu, X., Xu, W., Roulland, S., Ceribelli, M., Zhang, X., Wilson, K. M., Chen, L., McKnight, C., Klumpp-Thomas, C., Thomas, C. J., Häupl, B., Oellerich, T., Rae, Z., Kelly, M. C., Ahn, I. E., Sun, C., Gaglione, E. M., Wilson, W. H., Wiestner, A., & Staudt, L. M. (2021). Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood cancer discovery, 2(6), 630-647. https://doi.org/10.1158/2643-3230.BCD-21-0063
Shaffer, Arthur L, et al. "Overcoming Acquired Epigenetic Resistance to BTK Inhibitors." Blood cancer discovery vol. 2,6 (2021): 630-647. doi: https://doi.org/10.1158/2643-3230.BCD-21-0063
Shaffer AL, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood Cancer Discov. 2021 Sep 14;2(6):630-647. doi: 10.1158/2643-3230.BCD-21-0063. eCollection 2021 Nov. PMID: 34778802; PMCID: PMC8580621.
Copy Download .nbib Format: NLM
Showing 49 to 56 of 56 entries